

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

阿里健康信息技術有限公司

(Incorporated in Bermuda with limited liability)

(Stock code: 00241)

EXTENSION OF LONG STOP DATE IN RELATION TO VERY SUBSTANTIAL ACQUISITION, CONNECTED TRANSACTION AND REVERSE TAKEOVER INVOLVING A NEW LISTING APPLICATION

This announcement is made by Alibaba Health Information Technology Limited (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

We refer to the announcement of the Company dated April 15, 2015 (the “**Announcement**”) in relation to, among other things, the Proposed Acquisition. Unless otherwise indicated, capitalized terms defined in the Announcement shall have the same meanings when used herein.

As disclosed in the Announcement, on April 8, 2015, the Company (as the purchaser) and Ali JK Investment (a wholly owned subsidiary of Alibaba Holding) and Mr. Chen (together with Ali JK Investment as the sellers) entered into a share purchase agreement pursuant to which the Company has conditionally agreed to acquire, and Ali JK Investment and Mr. Chen have conditionally agreed to sell, at completion, the entire issued share capital of the Target Company.

Completion of the Proposed Acquisition is conditional upon the satisfaction (or, if applicable, the waiver) of a number of conditions precedent set out in the Agreement, including obtaining required regulatory approvals. If any of the conditions precedent has not been fulfilled (or waived) on or before December 31, 2015, or such later date as may be agreed in writing between the Company and the Vendors, the Agreement would automatically terminate with immediate effect pursuant to its terms.

The board of directors (the “**Board**”) of the Company wishes to inform the Shareholders that, as additional time is required for the fulfillment of the relevant conditions precedent, the Company and the Vendors have agreed to extend the long stop date of the fulfillment of the conditions precedent under the Agreement from December 31, 2015 to March 31, 2016 or such other date as may be agreed in writing between the Company and the Vendors. Save for the above extension, all other terms and conditions of the Agreement shall remain in full force and effect.

The Proposed Acquisition is subject to a number of conditions including but not limited to Independent Shareholders’ approval, which may or may not be fulfilled. In addition, the Listing Committee’s approval to the New Listing Application may or may not be granted. While the Company remains committed to pursuing the Proposed Acquisition, there remains uncertainty regarding obtaining the required regulatory approvals for the Proposed Acquisition.

In the event that the approval of the New Listing Application is not granted by the Listing Committee, the Agreement will not become unconditional and the Proposed Acquisition will not proceed. Shareholders and potential investors should exercise caution when they deal or contemplate dealing in the Shares or other securities of the Company.

By Order of the Board
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED
WANG Lei
Chief Executive Officer and Executive Director

Hong Kong, January 4, 2016

As at the date of this announcement, the Board comprises nine Directors, of which (i) two are executive Directors, namely, Ms. CHEN Xiao Ying and Mr. WANG Lei; (ii) four are non-executive Directors, namely, Mr. WU Yongming, Mr. TSAI Chung, Joseph, Ms. HUANG Aizhu and Mr. KANG Kai; and (iii) three are independent non-executive Directors, namely Mr. YAN Xuan, Mr. LUO Tong and Mr. WONG King On, Samuel.